Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer

Authors
Shim, J.-I.Ryu, J.-Y.Jeong, S.Y.Cho, Y.-J.Choi, J.-J.Hwang, J.R.Choi, J.-Y.Sa, J.K.Lee, J.-W.
Issue Date
5월-2022
Publisher
Academic Press Inc.
Keywords
5-AZA; Animal model; Epithelial ovarian cancer; Olaparib; Patient-derived xenograft
Citation
Gynecologic Oncology, v.165, no.2, pp.270 - 280
Indexed
SCIE
SCOPUS
Journal Title
Gynecologic Oncology
Volume
165
Number
2
Start Page
270
End Page
280
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/140498
DOI
10.1016/j.ygyno.2022.03.005
ISSN
0090-8258
Abstract
Objective: Poly (ADP)-ribose polymerase inhibitors (PARPi) are effective clinical agents for treatment of epithelial ovarian cancer (EOC) harboring BRCA mutations as well as those without BRCA mutations. In this study, we evaluate the efficacy of combined PARPi and DNA methyltransferase inhibitor (DNMTi) in EOCs. Methods: Expression levels of DNMT1 and PARP1 proteins in EOC cells were assessed using western blot analysis and immunohistochemistry. To evaluate the effects of co-treatment of PARPi (olaparib) and DNMTi (5-azacitidine, 5-AZA), we performed cell proliferation, apoptosis, and wound-healing assays in EOC cells. In addition, we performed in vivo experiments using both cell-line and patient-derived xenograft (PDX) models of EOC. Results: The combination of olaparib and 5-AZA significantly inhibited cell proliferation and migration and induced apoptosis compared with olaparib or 5-AZA alone in EOC cell lines including A2780, HeyA8, A2780-CP20, and HeyA8-MDR. Moreover, in vivo experiments with this combination showed significantly decreased weight and nodule numbers of tumors in cell-line xenograft models with A2780 cells and a PDX model compared with control, olaparib, and 5-AZA groups. As a potential mechanism, the expression of intracellular reactive oxygen species (ROS) and its related proteins, including p-ERK, NRF2, p-p38, HO-1, and γH2AX, was affected in EOC cells. Conclusions: Co-treatment with PARPi and DNMTi had a significant anti-tumor effect in EOC cells. This combination might be a potential therapeutic strategy for EOCs. © 2022
Files in This Item
There are no files associated with this item.
Appears in
Collections
Graduate School > Department of Biomedical Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE